Cargando…

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

AMPK is an energy sensor modulating metabolism, inflammation, and a target for metabolic disorders. Metabolic dysfunction results in lower AMPK activity. PXL770 is a direct AMPK activator, inhibiting de novo lipogenesis (DNL) and producing efficacy in preclinical models. We aimed to assess pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fouqueray, Pascale, Bolze, Sebastien, Dubourg, Julie, Hallakou-Bozec, Sophie, Theurey, Pierre, Grouin, Jean-Marie, Chevalier, Clémence, Gluais-Dagorn, Pascale, Moller, David E., Cusi, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714938/ https://www.ncbi.nlm.nih.gov/pubmed/35028615 http://dx.doi.org/10.1016/j.xcrm.2021.100474

Ejemplares similares

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
por: Theurey, Pierre, et al.
Publicado: (2022)

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
por: Hallakou-Bozec, Sophie, et al.
Publicado: (2021)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin
por: Theurey, Pierre, et al.
Publicado: (2022)

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects
por: Fouqueray, Pascale, et al.
Publicado: (2022)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis
por: Gluais‐Dagorn, Pascale, et al.
Publicado: (2021)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period
por: Reilhac, Caroline, et al.
Publicado: (2022)

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats
por: Hallakou‐Bozec, Sophie, et al.
Publicado: (2020)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
por: Detaille, D, et al.
Publicado: (2016)

Short‐and long‐term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome
por: Lachaux, Marianne, et al.
Publicado: (2020)

Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy
por: Monternier, Pierre‐Axel, et al.
Publicado: (2022)

Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
por: Cusi, Kenneth
Publicado: (2016)

Spatiotemporal regulation of cAMP signaling controls the human trophoblast fusion
por: Gerbaud, Pascale, et al.
Publicado: (2015)

The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells
por: Vial, Guillaume, et al.
Publicado: (2021)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Counteracting Roles of AMP Deaminase and AMP Kinase in the Development of Fatty Liver
por: Lanaspa, Miguel A., et al.
Publicado: (2012)

Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
por: Chang, Eugene, et al.
Publicado: (2013)

Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance
por: Yki-Järvinen, Hannele
Publicado: (2015)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection
por: Engwerda, Elsemiek E. C., et al.
Publicado: (2017)

MON-644 Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Fanous, Nada, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats
por: Roche‐Catholy, Marine, et al.
Publicado: (2022)

Pharmacodynamic properties for inhibition of cAMP- and cGMP elimination by pentoxifylline remain unaltered in vitro during hypothermia
por: Selli, Anders Lund, et al.
Publicado: (2022)

Acute regulation of 5′-AMP-activated protein kinase by long-chain fatty acid, glucose and insulin in rat primary adipocytes
por: Hebbachi, Abdel, et al.
Publicado: (2012)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study
por: Liu, Hui, et al.
Publicado: (2022)

Fatty liver biomarkers and insulin resistance indices in the prediction of non‐alcoholic fatty liver disease in Ghanaian patients
por: Bockarie, A. S., et al.
Publicado: (2023)

Comment on: Høeg et al. Lipid-Induced Insulin Resistance Affects Women Less Than Men and Is Not Accompanied by Inflammation or Impaired Proximal Insulin Signaling. Diabetes 2011;60:64–73
por: Cusi, Kenneth
Publicado: (2011)

Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection
por: Lu, Jiangjie, et al.
Publicado: (2020)

AMP-activated Protein Kinase α2 Subunit Is Required for the Preservation of Hepatic Insulin Sensitivity by n-3 Polyunsaturated Fatty Acids
por: Jelenik, Tomas, et al.
Publicado: (2010)

Top quark physics with ATLAS &amp;amp;amp;amp; CMS
por: Onofre, A
Publicado: (2009)

The Aging Mitochondria
por: Theurey, Pierre, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model
por: Zykov, Ilya Nikolaevich, et al.
Publicado: (2018)

cAMP Signaling in Pathobiology of Alcohol Associated Liver Disease
por: Elnagdy, Mohamed, et al.
Publicado: (2020)

Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children
por: Erol, Meltem, et al.
Publicado: (2016)

Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males
por: Akahane, Takemi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_id291epmprmvaegua94n9rqc76